Eric OBrien - Feb 2, 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC (GRNA)

Role
Director, 10%+ Owner
Signature
/s/ David Kennedy, Attorney-in-fact
Stock symbol
GRNA
Transactions as of
Feb 2, 2022
Transactions value $
$7,000,000
Form type
4
Date filed
2/4/2022, 06:32 PM
Next filing
Aug 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRNA Common Stock Award +8.2M 8.2M Feb 2, 2022 by Fall Line Endurance Fund, LP F1, F2
transaction GRNA Common Stock Purchase $7M +700K +8.53% $10.00* 8.9M Feb 2, 2022 by Fall Line Endurance Fund, LP F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the terms of a business combination agreement involving the issuer and GreenLight Biosciences, Inc. in exchange for capital stock previously issued by such company.
F2 Mr. O'Brien, a director of the Issuer, is the co-founder and Managing Director of Fall Line Endurance Fund, LP and has the power to vote, or to direct the voting of, the shares held by Fall Line Endurance Fund, LP. By virtue of the foregoing, Mr. O'Brien may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Exchange Act) the shares held by Fall Line Endurance Fund, LP. Mr. O'Brien disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.
F3 Amount consists of 700,000 shares of common stock issued pursuant to a subscription agreement entered into between the Issuer and Fall Line Endurance Fund, LP.